U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07060313) titled 'TARGETING DUAL PATHWAYS IN REFRACTORY COCCYDYNIA' on July 08.
Brief Summary: This retrospective cohort study included 60 patients aged 18-65 years treated at a tertiary pain clinic between June 2022 and June 2024. Patients received either Ganglion Impar Block (GIB) alone or GIB combined with pericoccygeal injection in a single session under fluoroscopic guidance. Pain severity and functional outcomes were assessed using the Numeric Rating Scale (NRS-11), Oswestry Disability Index (ODI), and Paris Functional Coccydynia Impact Questionnaire (PFCIQ) before the procedure and at 1 and 3 months post-intervention.
Study Start Date: June 0...